| Literature DB >> 28678857 |
O B Shevelev1, N B Illarionova1, D V Petrovski1, A P Sarapultsev2,3, O N Chupakhin3,4, M P Moshkin1,5.
Abstract
The aim of the present study was to examine how administration of a compound of 1,3,4- thiadiazine class 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide (L-17) with hypothermia inducing properties affects the brain metabolism. The mechanism by which L-17 induces hypothermia is unknown; it may involve hypothalamic central thermoregulation as well as act via inhibition of energy metabolism. We tested the hypothesis that L-17 may induce hypothermia by directly inhibiting energy metabolism. The study in vivo was carried out on Sprague-Dawley adult rats. Two doses of L-17 were administered (190 mg/kg and 760 mg/kg). Brain metabolites were analyzed in control and treated groups using magnetic resonance spectroscopy, along with blood flow rate measurements in carotid arteries and body temperature measurements. Further in vitro studies on primary cultures from rat hippocampus were carried out to perform a mitochondria function test of L-17 pre-incubation (100 μM, 30 min). Analysis of brain metabolites showed no significant changes in 190 mg/kg treated group along with a significant reduction in body temperature by 1.5°C. However, administration of L-17 in higher dose 760 mg/kg provoked changes in brain metabolites indicative of neurotoxicity as well as reduction in carotid arteries flow rate. In addition, a balance change of excitatory and inhibitory neurotransmitters was observed. The L-17 pre-incubation with cell primary cultures from rat brain showed no significant changes in mitochondrial function. The results obtained in the study indicate that acute administration of L-17 190 mg/kg in rats induces mild hypothermia with no adverse effects onto brain metabolism.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28678857 PMCID: PMC5498073 DOI: 10.1371/journal.pone.0180739
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1A Position of a voxel during 1H NMR spectroscopy of the brain cortex, and B a representative 1H NMR spectrum.
Ins, myo-inositol; PCr, phosphocreatine; Cr, creatine; Glu, glutamic acid; Gln, glutamine; Tau, taurine; Asp, aspartate; NAA, N-acetylaspartate; GABA, gamma-aminobutyric acid; MM, macromolecules; Ala, alanine; and Lac, lactate.
Fig 2A Structural formula of L-17. B Changes in body temperature after L-17 intraperitoneal injection 190 mg/kg and (C) blood flow velocity. Mann-Whitney U test significant difference from control group ***-p<0.001 n = 8 in (B) and One-way ANOVA * p<0.05 significant difference from control group in (C), followed by Post-hoc LSD test.
Levels of brain cortex metabolites in control and experimental rats, expressed as the percentage of the total number of molecules detected with 1H MRS.
NAA, N-acetylaspartate; GABA, gamma-aminobutyric acid; Ala, alanine; Ast, aspartate; Cho, choline; Cr, creatine; PCr, phosphocreatine; Glu, glutamic acid; Gln, glutamine; mIno, myo-inositol; Tau, taurine; Gly, glycine; Lac, lactate; PEA, phosphorylethanolamine.
| NAA % | GABA % | Ala % | Ast % | Cho % | Cr % | |
| Control (N = 7) | 16.02±0.45 | 5.52±0.40 | 5.25±2.17 | 0.24±0.09 | 0.94±0.20 | 9.98±0.35 |
| L17 low dose (N = 7) | 16.30±0.63 | 6.56±1.65 | 6.62±2.57 | 0.51±0.36 | 0.79±0.29 | 11.06±0.87 |
| L17 high dose (N = 5) | 13.94±0.27 | 3.54±1.18 | 3.73±1.13 | 1.03±0.94 | 0.64±0.27 | 9.91±0.49 |
| Glu+Gln % | mIno % | Tau % | Gly % | Lac % | PEA % | |
| Control (N = 7) | 13.18±0.54 | 1.54±0.84 | 4.44±0.49 | 20.80±4.03 | 6.64±1.45 | 15.46±1.35 |
| L17 low dose (N = 7) | 14.23±2.12 | 6.34±2.32 | 4.76±0.44 | 13.48±4.34 | 5.48±1.46 | 13.86±2.85 |
| L17 high dose (N = 5) | 16.33±2.79 | 1.87±1.83 | 6.14±0.53 | 22.83±6.93 | 4.01±1.55 | 16.04±4.70 |
*–significant difference from the control group (p<0.05, One-way ANOVA, Post-hoc LSD test)
#–significant difference from the control group (p<0.01, One-way ANOVA, Post-hoc LSD test)
Fig 3Correlations of individual metabolites with the integral characteristics of metabolic patterns (the values of the Y1) in rat brain cortex (A); values of the Y1 in rat brain cortex (B).
PEA—phosphorylethanolamine; Lac—lactate; Gly—glycine; Tau—taurine; Ins—myo-inositol; Glu—glutamic acid; Gln—glutamine; Cr—creatine; PCr—Phosphocreatine; Cho—choline; Asp—aspartate; Ala—alanine; GABA—gamma-aminobutyric acid; NAA—N-acetylaspartate.
Fig 4Respiration (OCR) is measured under basal conditions and in response to mitochondrial inhibitors (Oligomycin (Olig), FCCP, Rotenone/Antimycine A (Rot)) in (A) mixed neuron and astrocyte culture (n = 9) and in (B) astrocyte culture (n = 9).
Dashed line—control, solid line—L-17 pre-incubation. No significant differences in basal respiration or in mitochondrial stress test assessment were observed in L-17 (100 μM, pre-treated 30 min) cell cultures compared with control.